About
IL-12 based treatments
Areas of Focus
Categories
Biologics & BiopharmaceuticalSan Diego & Southern California
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
5
As Collaborator
0
Total Enrollment
300
By Phase
PHASE2: 4PHASE1: 1
By Status
COMPLETED: 3UNKNOWN: 2
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
Today
Hover over trial bars to see details
Recent Trials
NCT02544724Lead Sponsor
NM-IL-12 (rHuIL-12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy
PHASE2Unknown
12 participants
Started: Nov 30, 2016 · Completed: Dec 31, 2017
NCT02544061Lead Sponsor
NM-IL-12 (rHuIL-12) in Subjects With Open Surgical Wounds
PHASE2Completed
18 participants
Started: Mar 1, 2016 · Completed: Feb 28, 2018
NCT02542124Lead Sponsor
NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT)
PHASE2Unknown
10 participants
Started: Dec 31, 2015 · Completed: May 31, 2019
NCT02343133Lead Sponsor
Safety Study of HemaMax™ (rHuIL-12) to Treat Acute Radiation Syndrome
PHASE2Completed
200 participants
Started: Jan 31, 2015 · Completed: Apr 30, 2016
NCT01742221Lead Sponsor
Safety and Tolerability of HemaMax™ (rHuIL-12) as Radiation Countermeasure
PHASE1Completed
60 participants
Started: Aug 31, 2012 · Completed: Dec 31, 2012
Locations (1)
Headquarters
Arcadia, CA, United States
Map
Loading map...